OBJECTIVES The objective of the study was to compare rate control versus atrial fibrillation (AF) catheter ablation strategies in patients with AF and heart failure (HF).
A trial fibrillation (AF) and heart failure (HF) are 2 common cardiac conditions associated with substantial morbidity, mortality, and cost on health care systems (1) (2) (3) (4) . The 2 conditions frequently coexist, and each may promote the other.
AF is present in up to 50% of patients with HF (5) .
AF in HF patients is associated with increased hospital stay, stroke, and mortality (6) (7) (8) . This may be at least partially attributed to the hemodynamic effects of AF caused by loss of atrial contraction along with irregular and/or rapid ventricular rates, which can lead to left ventricular dysfunction and decreased cardiac output (9, 10) . The aim of our study was to determine if AF catheter ablation is superior to rate control in patients with AF and HF. We performed a meta-analysis of randomized, controlled trials that compared AF catheter ablation with rate control in patients with HF and AF.
METHODS

This meta-analysis of clinical trials was performed according to the guidelines of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) (17) . Table 1 .
All of the included trials were of high quality ($3/5) according to the Jadad quality assessment score.
None of the included trials attempted doubleblinding. Dropouts and withdrawals were described appropriately in the included trials. The blanking period ranged from 2 to 3 months. The percentage of patients requiring repeat procedures ranged from 19.5% to 53.7%. Only 1 study had cross-over of patients, and intention-to-treat analysis was used ( Table 2 ).
OUTCOMES. L V E F . Data for LVEF were available from all included trials. There was no significant heterogeneity (I 2 ¼ 0%) nor detectable publication bias. Quality of life and functional capacity measures.
Catheter ablation was superior to rate-control strategy in improving quality of life. Data on MLWHF were available from all the included trials. Across the included trials, there was no evidence of significant heterogeneity (I 2 ¼ 8%) or publication bias. There was a significant improvement in MLWHF questionnaire Figure 2D ). S e n s i t i v i t y a n a l y s e s . One trial included patients with both paroxysmal and persistent AF, in addition to the use of AV node ablation with biventricular pacing as a rate-control strategy (22 
We were able to obtain previously unpublished data on complications and incorporate them into our analysis from 2 RCTs (23,24). Two strokes, 4
cardiac tamponades, and 1 pericardial effusion were seen in the AF catheter ablation, culminating in a procedural complication rate of 6.3%. Details of complications and adverse events are listed in Table 3 .
Overall, no statistically significant difference was found in the major adverse event rates between the AF catheter ablation (7.2%) versus the rate-control 
DISCUSSION
We present the first meta-analysis of high-quality prospective, RCTs comparing AF catheter ablation versus rate-control strategies in patients with HF and AF.
Previous meta-analyses have relied mainly on data from observational studies in addition to a small number of RCTs (26) (27) (28) . This resulted in heterogeneity that was highly significant, raising un- . Mean difference and 95% confidence intervals (CIs) in studies comparing atrial fibrillation catheter ablation with rate control in patients with heart failure. IV ¼ inverse variance; SD ¼ standard deviation.
Al Halabi et al. We sought evidence from RCTs in an attempt to limit the influence of selection bias and control for unmeasured confounders (29) . We also targeted the specific patient population of HF with reduced LVEF and documented AF instead of including HF with preserved LVEF. At least 6 months of follow-up was chosen partially to control for differences in the use of AAD after AF catheter ablation (30) .
A significant improvement in LVEF was seen with the AF catheter ablation strategy in comparison to the rate-control approaches. The trend in improvement of LVEF was evident among all of the included RCTs.
Of note, 22% to 50% of patients were still in AF after AF catheter ablation, which suggests a role for reduction of AF burden rather than AF cure, leading to the aforementioned benefits. Another possibility is that patients may have had better follow-up and potentially better overall medical care in the AF catheter ablation group ( Table 2) . Catheter ablation is an invasive procedure, which may provide benefits but also carries well-known 
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risks, such as stroke, pericardial tamponade, pericarditis, bleeding, pulmonary stenosis, atrio-esophageal fistula, and even death, risks that may be even higher in a population with HF. The AF catheter ablation peri-procedural major complication rate in this study was 6.3%. Despite the structural changes seen in patients with reduced LVEF, the reported AF catheter ablation complication rate in this metaanalysis is comparable to, though perhaps slightly higher than, AF catheter ablation complication rates reported in a large prospective study (5.2%) and a recent meta-analysis in patients with structurally normal hearts (2.7% to 3.5%) (36, 37) . The trend toward higher adverse event rates compared with the rate-control group (p ¼ 0.17) suggests there may be a price paid for improving the other outcomes measured in this study. Given the overall low adverse event rates, our study was probably under-powered to detect statistically significant differences in adverse events. These risks are put in context to the ratecontrol adverse event rates in this study of 12.5% in the pharmacological rate-control studies and 10% in the study using AV node ablation and biventricular pacing. Cross-over occurred in one trial in only 2 patients, making it less likely that cross-overs can explain the comparability in the incidence of major complications. It is perhaps more plausible that AF ablation was associated with relatively low rates of major adverse event complications, such as death or stroke (<1%), in these studies (38) .
The majority (82.5%) of patients in the current study had persistent AF; therefore, results may not be easily extrapolated to a population with paroxysmal AF. However, this high proportion of patients with persistent AF, as well as the sensitivity analyses demonstrating similar efficacy of AF catheter catheter ablation with rate control in patients with heart failure. M-H ¼ Mantel-Haenszel.
Al Halabi et al. however, we were limited by the available trials in the literature. Nevertheless, the mean LVEF of patients was <35% in all studies, NYHA functional class was predominantly 2 to 3, and complication and adverse event rates were at the higher end of that reported in the literature, which suggests that these patients might be representative of a HF population at large.
Last, PVI alone was not used in the majority of cases;
after PVI, additional atrial substrate modification was used to varying degrees in each study. However, these approaches reflect contemporary local practice for catheter ablation of persistent AF. Selecting the strategy to address AF in heart failure should consider several factors, including the type of AF and patient preferences.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
A strategy of AF catheter ablation may lead to improvement of AF with improvements in left ventricular function and functional capacity.
TRANSLATIONAL OUTLOOK:
The mortality rate associated with AF catheter ablation versus ratecontrol strategy is an important potential area of research.
Al Halabi et al. 
